Searching for the needle in the haystack: deconvoluting the evolutionary dynamics of residual disease in human glioblastoma

doi:10.1093/annonc/mdz042

Editorial

. 2019 Mar 1;30(3):355-357.

doi: 10.1093/annonc/mdz042.

Searching for the needle in the haystack: deconvoluting the evolutionary dynamics of residual disease in human glioblastoma

S T C Shepherd¹, K Litchfield², S Turajlic³

Affiliations

¹ The Renal and Melanoma Unit, The Royal Marsden NHS Foundation Trust, London; Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK.
² Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK.
³ The Renal and Melanoma Unit, The Royal Marsden NHS Foundation Trust, London; Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK. Electronic address: samra.turajlic@crick.ac.uk.

PMID: 30753265
PMCID: PMC6442653
DOI: 10.1093/annonc/mdz042

Editorial

Searching for the needle in the haystack: deconvoluting the evolutionary dynamics of residual disease in human glioblastoma

S T C Shepherd et al. Ann Oncol. 2019.

. 2019 Mar 1;30(3):355-357.

doi: 10.1093/annonc/mdz042.

Authors

S T C Shepherd¹, K Litchfield², S Turajlic³

Affiliations

¹ The Renal and Melanoma Unit, The Royal Marsden NHS Foundation Trust, London; Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK.
² Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK.
³ The Renal and Melanoma Unit, The Royal Marsden NHS Foundation Trust, London; Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK. Electronic address: samra.turajlic@crick.ac.uk.

PMID: 30753265
PMCID: PMC6442653
DOI: 10.1093/annonc/mdz042

No abstract available

PubMed Disclaimer

Figures

**Figure 1.**
Residual disease in glioblastoma. (A) At surgery, only the primary tumour mass (red online) is removed (in dark grey the resection cavity). (B) However, infiltrative cells in the normal brain parenchyma (green online) and sub-ventricular zone (SVZ) (blue online) are left behind. (C) Residual glioblastoma cells infiltrated throughout the brain can give rise to relapse, both locally and distally. Reproduced this figure with permission from Spiteri et al. [2].

See this image and copyright information in PMC

Comment on

Evolutionary dynamics of residual disease in human glioblastoma.
Spiteri I, Caravagna G, Cresswell GD, Vatsiou A, Nichol D, Acar A, Ermini L, Chkhaidze K, Werner B, Mair R, Brognaro E, Verhaak RGW, Sanguinetti G, Piccirillo SGM, Watts C, Sottoriva A. Spiteri I, et al. Ann Oncol. 2019 Mar 1;30(3):456-463. doi: 10.1093/annonc/mdy506. Ann Oncol. 2019. PMID: 30452544 Free PMC article.

Cited by

Tumor DNA From Tumor In Situ Fluid Reveals Mutation Landscape of Minimal Residual Disease After Glioma Surgery and Risk of Early Recurrence.
Yu J, Sheng Z, Wu S, Gao Y, Yan Z, Bu C, Gu J, Bu Y, Deng K, Xu S, Chen Z, Zhang Q, Zemmar A, Hernesniemi J, Wang M, Liu G, Li T, Bu X. Yu J, et al. Front Oncol. 2021 Oct 11;11:742037. doi: 10.3389/fonc.2021.742037. eCollection 2021. Front Oncol. 2021. PMID: 34712610 Free PMC article.

References

1. McGranahan N, Swanton C.. Clonal heterogeneity and tumor evolution: past, present, and the future. Cell 2017; 168(4): 613–628. - PubMed
1. Spiteri I, Caravagna G, Cresswell GD. et al. Evolutionary dynamics of residual disease in human glioblastoma. Ann Oncol 2019; 30(3): 456–463. - PMC - PubMed
1. Wen PY, Kesari S.. Malignant gliomas in adults. N Engl J Med 2008; 359(5): 492–507. - PubMed
1. Stupp R, Mason WP, van den Bent MJ. et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005; 352(10): 987–996. - PubMed
1. Rapp M, Baernreuther J, Turowski B. et al. Recurrence pattern analysis of primary glioblastoma. World Neurosurg 2017; 103: 733–740. - PubMed

Publication types

Actions
Actions
Actions

MeSH terms

Actions
Actions
Actions

Grants and funding

LinkOut - more resources

Full Text Sources

[1] McGranahan N, Swanton C.. Clonal heterogeneity and tumor evolution: past, present, and the future. Cell 2017; 168(4): 613–628. - PubMed

[2] McGranahan N, Swanton C.. Clonal heterogeneity and tumor evolution: past, present, and the future. Cell 2017; 168(4): 613–628. - PubMed

[3] Spiteri I, Caravagna G, Cresswell GD. et al. Evolutionary dynamics of residual disease in human glioblastoma. Ann Oncol 2019; 30(3): 456–463. - PMC - PubMed

[4] Spiteri I, Caravagna G, Cresswell GD. et al. Evolutionary dynamics of residual disease in human glioblastoma. Ann Oncol 2019; 30(3): 456–463. - PMC - PubMed

[5] Wen PY, Kesari S.. Malignant gliomas in adults. N Engl J Med 2008; 359(5): 492–507. - PubMed

[6] Wen PY, Kesari S.. Malignant gliomas in adults. N Engl J Med 2008; 359(5): 492–507. - PubMed

[7] Stupp R, Mason WP, van den Bent MJ. et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005; 352(10): 987–996. - PubMed

[8] Stupp R, Mason WP, van den Bent MJ. et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005; 352(10): 987–996. - PubMed

[9] Rapp M, Baernreuther J, Turowski B. et al. Recurrence pattern analysis of primary glioblastoma. World Neurosurg 2017; 103: 733–740. - PubMed

[10] Rapp M, Baernreuther J, Turowski B. et al. Recurrence pattern analysis of primary glioblastoma. World Neurosurg 2017; 103: 733–740. - PubMed

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Searching for the needle in the haystack: deconvoluting the evolutionary dynamics of residual disease in human glioblastoma

Affiliations

Searching for the needle in the haystack: deconvoluting the evolutionary dynamics of residual disease in human glioblastoma

Authors

Affiliations

Figures

Comment on

Similar articles

Cited by

References

Publication types

MeSH terms

Grants and funding

LinkOut - more resources

Full Text Sources